An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Public ClinicalTrials.gov record NCT01803867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.
Study identification
- NCT ID
- NCT01803867
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2013
- Primary completion
- Sep 30, 2014
- Completion
- Dec 31, 2014
- Last update posted
- Feb 26, 2015
2013 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Acorda Investigational Site | Long Beach | California | 90806 | — |
| Acorda Investigational Site | Palo Alto | California | 04158 | — |
| Acorda Investigational Site | Sacramento | California | 95817 | — |
| Acorda Investigational Site | Stanford | California | 94305-5235 | — |
| Acorda Investigational Site | Aurora | Colorado | 80045 | — |
| Acorda Investigational Site | Centennial | Colorado | 80112 | — |
| Acorda Investigational Site | Indianapolis | Indiana | 46202 | — |
| Acorda Investigational Site | Kansas City | Kansas | 66160 | — |
| Acorda Investigational Site | Baltimore | Maryland | 22125 | — |
| Acorda Investigational Site | St Louis | Missouri | 63131 | — |
| Acorda Investigational Site | Rochester | New York | 14642 | — |
| Acorda Investigational Site | Providence | Rhode Island | 02905 | — |
| Acorda Investigational Site | Knoxville | Tennessee | 37920 | — |
| Acorda Investigational Site | Dallas | Texas | 75390-9036 | — |
| Acorda Investigational Site | Burlington | Vermont | 05401 | — |
| Acorda Investigational Site | Seattle | Washington | 98101 | — |
| Acorda Investigational Site | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01803867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01803867 live on ClinicalTrials.gov.